Nanotechnology Now - Press Release: Octillion Appoints Mr. Barry Honig to Newly Formed Advisory Board

Home > Press > Octillion Appoints Mr. Barry Honig to Newly Formed Advisory Board

Abstract:
Octillion Corp. (Symbol: OCTL), an alternative energy technology incubator, is pleased to announce the appointment of Mr. Barry Honig to its newly established Advisory Board, which will be comprised of respected experts in solar energy and solar related technologies, mergers and acquisitions and corporate finance.

Octillion Appoints Mr. Barry Honig to Newly Formed Advisory Board

Auburn Hills, MI | Posted on October 22nd, 2007

Mr. Honig is a highly regarded venture capital investor and coveted advisor to numerous early stage companies. He has assisted many companies with going public via reverse mergers, successfully raising significant amounts of capital and achieving listings on the NASDAQ Stock Market, including: Infologix Inc. (NASDAQ: IFLG), Akeena Solar (NASDAQ: AKNS), Neuro Hitech Inc. (NASDAQ: NHPI), Health Benefits (HBDT), Handheld Entertainment (NASDAQ: ZVUE), Towerstream Corp. (NASDAQ: TWER), China Clean Energy (CCGY) and Novelos Therapeutics (NVLT).

Mr. Honig, whose particular expertise is in corporate finance, capital structure, debt financings, and mergers and acquisitions, comments, "I am excited to join the Octillion team and look forward to creating significant shareholder value by leveraging numerous, long standing relationships that I have established during my career."

"The Advisory Board is being formed to augment and complement the Company's management team and to enhance Octillion's sphere of opportunity," stated Mr. Nicholas S. Cucinelli, Octillion's President and CEO. "As an alternative energy technology incubator, we not only need cutting edge technologies in our portfolio, but also the intellectual capital to move these technologies through the research and development stage and onto commercialization. In addition to Mr. Honig, we will be further building our Advisory Board with new members in the near future."

####

About Octillion Corp.
Octillion Corp. is an alternative energy technology incubator focused on the identification, acquisition, development and eventual commercialization of emerging solar energy and solar related technologies.

Among our current research and development activities is the development of a technology that has the potential of adapting existing home and office glass windows into ones capable of generating electricity from solar energy without losing significant transparency or requiring major changes in manufacturing infrastructure.

The technological potential of adapting existing glass windows into ones capable of generating electricity from the sun’s solar energy has been made possible through a ground breaking discovery of an electrochemical and ultrasound process that produces identically sized (1 to 4 nanometers in diameter) highly luminescent nanoparticles of silicon that provide varying wavelengths of photoluminescence with high quantum down conversion efficiency of short wavelengths (50% to 60%).

When thin films of silicon nanoparticles are deposited (sprayed) onto silicon substrates, ultraviolet light is absorbed and converted into electrical current. With appropriate connections, the film acts as nanosilicon photovoltaic solar cells that convert solar radiation to electrical energy.

For additional information, please visit: http://www.octillioncorp.com

To receive future press releases via email, please visit:
http://www.octillioncorp.com/contact.html

To view the full HTML text of this release, please visit:
http://www.octillioncorp.com/OCTL_20071022.html

Legal Notice Regarding Forward-Looking Statements

No statement herein should be considered an offer or a solicitation of an offer for the purchase or sale of any securities. This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although Octillion Corp. (the “Company” or “Octillion”) believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, adverse federal, state and local government regulation, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, termination of contracts or agreements, technological obsolescence of the Company's products, technical problems with the Company's research and products, price increases for supplies and components, litigation and administrative proceedings involving the Company, the possible acquisition of new businesses or technologies that result in operating losses or that do not perform as anticipated, unanticipated losses, the possible fluctuation and volatility of the Company's operating results, financial condition and stock price, losses incurred in litigating and settling cases, dilution in the Company's ownership of its business, adverse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists, changes in interest rates, inflationary factors, and other specific risks. We currently have no commercial products intended to diagnose, treat, prevent or cure any disease. The statements contained in this press release regarding our on going research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration. There can be no assurance that further research and development, and /or whether clinical trial results, if any, will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that Octillion will be able to develop commercially viable products on the basis of its technologies. In addition, other factors that could cause actual results to differ materially are discussed in the Company's most recent Form 10-QSB and Form 10-KSB filings with the Securities and Exchange Commission. These reports and filings may be inspected and copied at the Public Reference Room maintained by the U.S. Securities & Exchange Commission at 100 F Street, N.E., Washington, D.C. 20549. You can obtain information about operation of the Public Reference Room by calling the U.S. Securities & Exchange Commission at 1-800-SEC-0330. The U.S. Securities & Exchange Commission also maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the U.S. Securities & Exchange Commission at http://www.sec.gov. The Company undertakes no obligation to publicly release the results of any revisions to these forward looking statements that may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.